IMKELDI is the first oral liquid form of imatinib for specific leukaemia cancer forms. Credit: Jo Panuwat D/Shutterstock.

The US Food and Drug Administration (FDA) has approved Shorla Oncology‘s IMKELDI to treat specific forms of leukaemia.

IMKELDI offers a liquid formulation of imatinib mesylate, a tyrosine kinase inhibitor. It is designed for use in adults and paediatric patients as young as one, targeting acute lymphoblastic leukaemia, chronic myeloid leukaemia, gastrointestinal stromal tumours and myelodysplastic syndrome/myeloproliferative disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Without requiring refrigeration, the strawberry-flavoured solution is intended to improve patient adherence and access to treatment. Its stable formulation aims to provide precise dosing.

Shorla Oncology CEO Sharon Cunningham stated: “We are thrilled to offer an oral solution option for patients with leukaemia and other cancers, a meaningful advancement for thousands in need.

“Oral solutions may ensure more precise and consistent dosing, offering a convenient alternative to compounding for patients who have difficulty swallowing or require dosing tailored to body surface area.”

The company announced the expanded FDA approval of JYLAMVO (methotrexate) in October 2024.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

JYLAMVO is approved for paediatric patients with acute lymphoblastic leukaemia (ALL) and polyarticular juvenile idiopathic arthritis, making it the sole oral liquid methotrexate approved for both adult and paediatric use.

In July 2024, the FDA approved a new drug application (NDA) for TEPYLUTE to treat breast and ovarian cancer.

Shorla Oncology co-founder and chief technical officer Orlaith Ryan stated: “This milestone marks our fourth FDA approval as we advance our mission to make existing oncology treatments better through formulation re-innovation.

“Our team is dedicated to creating more patient-friendly options that address real needs in those suffering from cancer.”